Table 1:
Wnt inhibitors used in the clinic
| Compound | Cancer type | Trial identifier |
|---|---|---|
| WNT ligand or receptor targeting agents | ||
| OMP-54F28 (Ipafricept) | Ovarian Pancreatic HCC |
NCT01608867
NCT02092363 NCT02050178 NCT02069145 |
| OMP-18R5/ Vanticumab | NSCLC Pancreatic Metastatic HER2-negative breast cancer |
NCT01345201
NCT01957007 NCT02005315 NCT01973309 |
| WNT974 (LGK974) | Pancreatic BRAF mutant and metastatic CRC Melanoma TNBC Head and Neck squamous cell cancer Cervical squamous cell cancer Esophageal squamous cell cancer Lung squamous cell cancer |
NCT01351103
NCT02278133 |
| ETC-1922159 | Advanced sold tumors | NCT02521844 |
| RXC004 | Solid tumors | NCT03447470 |
| Compounds that promote β-catenin degradation | ||
| CWP232291 | AML CML Myelodysplastic syndrome Myelofibrosis Multiple Myeloma |
NCT03055286
NCT01398462 NCT02426723 |
| E7–447 (2X-121) | Ovarian Breast Solid tumors TNBC Melanoma |
NCT03878849
NCT03562832 NCT01618136 |
| Antagonist of β-catenin mediated expression | ||
| PRI-724 | Pancreatic AML CML CRC |
NCT01764477
NCT01606579 NCT02413853 |
| E7386 | Solid neoplasms CRC neoplasms |
NCT03833700
NCT03264664 |
| SM08502 | Solid tumors | NCT0335066 |